CYNATA THERAPEUTICS LIMITED - Announcements

Market Cap $37.72M Add to my watchlist

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) is stepping up its trial activities in Australia’s nearest Asian neighbour, Indonesia. Recce’s flagship anti-infective, R327, can be applied as a gel – and this gel-based version of the drug has been of specific interest...

Announcements

Filter Results

All Price Sensitive Only

CYP	Notification regarding unquoted securities - CYP		17/04/24	18.39KB	Share
CYP	DFU Clinical Trial Enrolment Complete	PRICE SENSITIVE	08/04/24	141.17KB	Share
CYP	EU Approval for Phase 2 CYP-001 Trial in GvHD	PRICE SENSITIVE	20/03/24	151.52KB	Share
CYP	Cynata Presenting at Advanced Therapies Congress		18/03/24	2.84MB	Share
CYP	First Patient Treated in Phase 2 GvHD Trial	PRICE SENSITIVE	05/03/24	154.43KB	Share
CYP	Cynata Appoints New Chief Business Officer		29/02/24	157.89KB	Share
CYP	Encouraging Initial Data from CYP-006TK DFU Trial	PRICE SENSITIVE	26/02/24	161.15KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	23/02/24	828KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	30/01/24	442.87KB	Share
CYP	Notification regarding unquoted securities - CYP		16/01/24	28.07KB	Share
CYP	Initial Results in First 16 DFU Patients Expected in Q1 2024		28/12/23	200.06KB	Share
CYP	Recruitment Completed in Phase 3 OA Clinical Trial	PRICE SENSITIVE	13/12/23	200.67KB	Share
CYP	Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey	PRICE SENSITIVE	07/12/23	198.02KB	Share
CYP	Appendix 3Y - Dr Kilian Kelly		23/11/23	192.82KB	Share
CYP	Appendix 3Ys x 5		20/11/23	283.16KB	Share
CYP	Notification regarding unquoted securities - CYP		20/11/23	28.61KB	Share
CYP	Notification of cessation of securities - CYP		14/11/23	21.75KB	Share
CYP	Cynata Receives $2.315m R&D Tax Incentive Refund	PRICE SENSITIVE	14/11/23	189.19KB	Share
CYP	Final Director's Interest Notice		13/11/23	159.93KB	Share
CYP	Results of AGM		13/11/23	271.81KB	Share
CYP	AGM Presentations		13/11/23	3.17MB	Share
CYP	Phase 3 SCUlpTOR Osteoarthritis Clinical Trial Progress		06/11/23	228.12KB	Share
CYP	First USA site initiated in aGvHD trial		02/11/23	221.47KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	26/10/23	451.39KB	Share
CYP	Annual Report to Shareholders		12/10/23	8.76MB	Share
CYP	Letter to Shareholders, Notice of AGM & Proxy Form		12/10/23	602.31KB	Share
CYP	Dr David Atkins not to stand for re-election at AGM		09/10/23	186.61KB	Share
CYP	Investor Webinar Presentation		18/09/23	3.86MB	Share
CYP	Date of AGM and Closing Date for Director Nominations		18/09/23	191.73KB	Share
CYP	Appendix 4G		28/08/23	288.01KB	Share
CYP	Corporate Governance Statement		28/08/23	358.08KB	Share
CYP	Appendix 4E & Annual Report	PRICE SENSITIVE	28/08/23	8.83MB	Share
CYP	Approval of Clinical Trial of CYP-001 in Kidney Transplant	PRICE SENSITIVE	21/08/23	226.05KB	Share
CYP	Phase 2 Trial of CYP-001 in aGvHD Open for Recruitment	PRICE SENSITIVE	10/08/23	224.51KB	Share
CYP	Investor Webinar Presentation		27/07/23	1.09MB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	26/07/23	479.33KB	Share
CYP	Ceasing to be a substantial holder		25/07/23	215.9KB	Share
CYP	Strategic Review of Cynata Clinical Development Portfolio	PRICE SENSITIVE	24/07/23	241.32KB	Share
CYP	Initial Director's Interest Notice - David Atkins		03/07/23	146.32KB	Share
CYP	Initial Director's Interest Notice - Kilian Kelly		03/07/23	148.35KB	Share
CYP	Final Director's Interest Notice - Stewart Washer		03/07/23	193.58KB	Share
CYP	Final Director's Interest Notice - Ross Macdonald		03/07/23	188.93KB	Share
CYP	Notification regarding unquoted securities - CYP		30/06/23	28.04KB	Share
CYP	Proposed issue of securities - CYP		30/06/23	26.37KB	Share
CYP	Cynata announces CEO succession and Board changes	PRICE SENSITIVE	30/06/23	274.49KB	Share
CYP	Change in substantial holding		15/06/23	670.08KB	Share
CYP	Appendix 3Ys x 6		01/06/23	532.98KB	Share
CYP	Top 20 Listed Optionholders & Distribution Schedule		01/06/23	130.73KB	Share
CYP	Application for quotation of securities - CYP		01/06/23	28.11KB	Share
CYP	Cleansing Notice		31/05/23	245.63KB	Share
CYP	Application for quotation of securities - CYP		31/05/23	24.75KB	Share
CYP	Results of Meeting		25/05/23	275.05KB	Share
CYP	Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT		22/05/23	269.16KB	Share
CYP	Application for quotation of securities - CYP		11/05/23	24.96KB	Share
CYP	Cynata Completes Oversubscribed Share Purchase Plan	PRICE SENSITIVE	10/05/23	240.96KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	28/04/23	479.44KB	Share
CYP	Proposed issue of securities - CYP		24/04/23	27.89KB	Share
CYP	Letter to Shareholders, Notice of Meeting & Proxy Form		24/04/23	1.08MB	Share
CYP	Cleansing Notice		24/04/23	245.49KB	Share
CYP	Application for quotation of securities - CYP		24/04/23	24.92KB	Share
CYP	Target Market Determination		19/04/23	179.68KB	Share
CYP	Share Purchase Plan Booklet & Option Prospectus	PRICE SENSITIVE	19/04/23	994.13KB	Share
CYP	Cleansing Notice		17/04/23	250.18KB	Share
CYP	Application for quotation of securities - CYP		17/04/23	24.96KB	Share
CYP	Ethics Committee Approval for Proposed aGvHD Phase 2 Trial	PRICE SENSITIVE	12/04/23	250.35KB	Share
CYP	Capital Raising Presentation	PRICE SENSITIVE	06/04/23	3.23MB	Share
CYP	Proposed issue of securities - CYP		06/04/23	43.43KB	Share
CYP	Cynata completes $5.0m Placement and launches SPP	PRICE SENSITIVE	06/04/23	299.75KB	Share
CYP	Trading Halt	PRICE SENSITIVE	04/04/23	298.18KB	Share
CYP	Notification of cessation of securities - CYP		03/04/23	21.68KB	Share
CYP	Cynata Adds New Sites for DFU Clinical Trial	PRICE SENSITIVE	16/03/23	260.1KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	28/02/23	815.32KB	Share
CYP	Notification of cessation of securities - CYP		06/02/23	21.68KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	31/01/23	507.29KB	Share
CYP	Cynata Receives IRB Approval for aGvHD Clinical Trial	PRICE SENSITIVE	30/01/23	252.05KB	Share
CYP	Notice of Acceptance for Cynata Australian Patent	PRICE SENSITIVE	09/01/23	249.94KB	Share
CYP	Notification of cessation of securities - CYP		05/01/23	21.68KB	Share
CYP	Cynata Receives $1.65m R&D Tax Incentive Refund	PRICE SENSITIVE	05/12/22	219.83KB	Share
CYP	Appendix 3Y - Janine Rolfe		23/11/22	175.39KB	Share
CYP	Notification regarding unquoted securities - CYP		23/11/22	27.78KB	Share
CYP	Results of AGM		22/11/22	248.11KB	Share
CYP	AGM Presentations		22/11/22	1.11MB	Share
CYP	Conference Data Demonstrating Consistency of Cynata MSCs		16/11/22	274.81KB	Share
CYP	Notice of Allowance for Cynata US Patent	PRICE SENSITIVE	11/11/22	249.75KB	Share
CYP	Notification of cessation of securities - CYP		07/11/22	21.66KB	Share
CYP	New Kidney Transplantation Clinical Trial for Cynata & LUMC	PRICE SENSITIVE	02/11/22	285.68KB	Share
CYP	Quarterly Activity Report & Appendix 4C	PRICE SENSITIVE	31/10/22	509.47KB	Share
CYP	Annual Report to Shareholders		21/10/22	6.5MB	Share
CYP	Letter to Shareholders, Notice of AGM & Proxy Form		21/10/22	1.01MB	Share
CYP	Notice of Allowance for Australia & Canada Cymerus Patents	PRICE SENSITIVE	17/10/22	249.47KB	Share
CYP	Successful Completion of Planned DSMB Review of DFU Trial	PRICE SENSITIVE	12/10/22	257.57KB	Share
CYP	Date of AGM and Closing Date for Director Nominations		27/09/22	216.12KB	Share
CYP	Grant Award to Fund Study of Cynata MSCs in Heart Disease	PRICE SENSITIVE	26/09/22	281.79KB	Share
CYP	Appendix 3X - Janine Rolfe		01/09/22	145.41KB	Share
CYP	Appointment of Ms Janine Rolfe to the Cynata Board		30/08/22	249.69KB	Share
CYP	Preclinical study in coronary artery disease published		29/08/22	256.27KB	Share
CYP	Appendix 4G		24/08/22	286.93KB	Share
CYP	Corporate Governance Statement		24/08/22	353.57KB	Share
CYP	Appendix 4E & Annual Report	PRICE SENSITIVE	24/08/22	6.67MB	Share
CYP	Pipeline Update Following Strategic Portfolio Review	PRICE SENSITIVE	12/08/22	309.54KB	Share

CYP Notification regarding unquoted securities - CYP
17/04/24		18.39KB	Share
CYP DFU Clinical Trial Enrolment Complete
08/04/24	PRICE SENSITIVE	141.17KB	Share
CYP EU Approval for Phase 2 CYP-001 Trial in GvHD
20/03/24	PRICE SENSITIVE	151.52KB	Share
CYP Cynata Presenting at Advanced Therapies Congress
18/03/24		2.84MB	Share
CYP First Patient Treated in Phase 2 GvHD Trial
05/03/24	PRICE SENSITIVE	154.43KB	Share
CYP Cynata Appoints New Chief Business Officer
29/02/24		157.89KB	Share
CYP Encouraging Initial Data from CYP-006TK DFU Trial
26/02/24	PRICE SENSITIVE	161.15KB	Share
CYP Appendix 4D & Half-Year Financial Statements
23/02/24	PRICE SENSITIVE	828KB	Share
CYP Quarterly Activity Report & Appendix 4C
30/01/24	PRICE SENSITIVE	442.87KB	Share
CYP Notification regarding unquoted securities - CYP
16/01/24		28.07KB	Share
CYP Initial Results in First 16 DFU Patients Expected in Q1 2024
28/12/23		200.06KB	Share
CYP Recruitment Completed in Phase 3 OA Clinical Trial
13/12/23	PRICE SENSITIVE	200.67KB	Share
CYP Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey
07/12/23	PRICE SENSITIVE	198.02KB	Share
CYP Appendix 3Y - Dr Kilian Kelly
23/11/23		192.82KB	Share
CYP Appendix 3Ys x 5
20/11/23		283.16KB	Share
CYP Notification regarding unquoted securities - CYP
20/11/23		28.61KB	Share
CYP Notification of cessation of securities - CYP
14/11/23		21.75KB	Share
CYP Cynata Receives $2.315m R&D Tax Incentive Refund
14/11/23	PRICE SENSITIVE	189.19KB	Share
CYP Final Director's Interest Notice
13/11/23		159.93KB	Share
CYP Results of AGM
13/11/23		271.81KB	Share
CYP AGM Presentations
13/11/23		3.17MB	Share
CYP Phase 3 SCUlpTOR Osteoarthritis Clinical Trial Progress
06/11/23		228.12KB	Share
CYP First USA site initiated in aGvHD trial
02/11/23		221.47KB	Share
CYP Quarterly Activity Report & Appendix 4C
26/10/23	PRICE SENSITIVE	451.39KB	Share
CYP Annual Report to Shareholders
12/10/23		8.76MB	Share
CYP Letter to Shareholders, Notice of AGM & Proxy Form
12/10/23		602.31KB	Share
CYP Dr David Atkins not to stand for re-election at AGM
09/10/23		186.61KB	Share
CYP Investor Webinar Presentation
18/09/23		3.86MB	Share
CYP Date of AGM and Closing Date for Director Nominations
18/09/23		191.73KB	Share
CYP Appendix 4G
28/08/23		288.01KB	Share
CYP Corporate Governance Statement
28/08/23		358.08KB	Share
CYP Appendix 4E & Annual Report
28/08/23	PRICE SENSITIVE	8.83MB	Share
CYP Approval of Clinical Trial of CYP-001 in Kidney Transplant
21/08/23	PRICE SENSITIVE	226.05KB	Share
CYP Phase 2 Trial of CYP-001 in aGvHD Open for Recruitment
10/08/23	PRICE SENSITIVE	224.51KB	Share
CYP Investor Webinar Presentation
27/07/23		1.09MB	Share
CYP Quarterly Activity Report & Appendix 4C
26/07/23	PRICE SENSITIVE	479.33KB	Share
CYP Ceasing to be a substantial holder
25/07/23		215.9KB	Share
CYP Strategic Review of Cynata Clinical Development Portfolio
24/07/23	PRICE SENSITIVE	241.32KB	Share
CYP Initial Director's Interest Notice - David Atkins
03/07/23		146.32KB	Share
CYP Initial Director's Interest Notice - Kilian Kelly
03/07/23		148.35KB	Share
CYP Final Director's Interest Notice - Stewart Washer
03/07/23		193.58KB	Share
CYP Final Director's Interest Notice - Ross Macdonald
03/07/23		188.93KB	Share
CYP Notification regarding unquoted securities - CYP
30/06/23		28.04KB	Share
CYP Proposed issue of securities - CYP
30/06/23		26.37KB	Share
CYP Cynata announces CEO succession and Board changes
30/06/23	PRICE SENSITIVE	274.49KB	Share
CYP Change in substantial holding
15/06/23		670.08KB	Share
CYP Appendix 3Ys x 6
01/06/23		532.98KB	Share
CYP Top 20 Listed Optionholders & Distribution Schedule
01/06/23		130.73KB	Share
CYP Application for quotation of securities - CYP
01/06/23		28.11KB	Share
CYP Cleansing Notice
31/05/23		245.63KB	Share
CYP Application for quotation of securities - CYP
31/05/23		24.75KB	Share
CYP Results of Meeting
25/05/23		275.05KB	Share
CYP Two-Year Results of Phase 1 SR-aGvHD Trial Presented at ISCT
22/05/23		269.16KB	Share
CYP Application for quotation of securities - CYP
11/05/23		24.96KB	Share
CYP Cynata Completes Oversubscribed Share Purchase Plan
10/05/23	PRICE SENSITIVE	240.96KB	Share
CYP Quarterly Activity Report & Appendix 4C
28/04/23	PRICE SENSITIVE	479.44KB	Share
CYP Proposed issue of securities - CYP
24/04/23		27.89KB	Share
CYP Letter to Shareholders, Notice of Meeting & Proxy Form
24/04/23		1.08MB	Share
CYP Cleansing Notice
24/04/23		245.49KB	Share
CYP Application for quotation of securities - CYP
24/04/23		24.92KB	Share
CYP Target Market Determination
19/04/23		179.68KB	Share
CYP Share Purchase Plan Booklet & Option Prospectus
19/04/23	PRICE SENSITIVE	994.13KB	Share
CYP Cleansing Notice
17/04/23		250.18KB	Share
CYP Application for quotation of securities - CYP
17/04/23		24.96KB	Share
CYP Ethics Committee Approval for Proposed aGvHD Phase 2 Trial
12/04/23	PRICE SENSITIVE	250.35KB	Share
CYP Capital Raising Presentation
06/04/23	PRICE SENSITIVE	3.23MB	Share
CYP Proposed issue of securities - CYP
06/04/23		43.43KB	Share
CYP Cynata completes $5.0m Placement and launches SPP
06/04/23	PRICE SENSITIVE	299.75KB	Share
CYP Trading Halt
04/04/23	PRICE SENSITIVE	298.18KB	Share
CYP Notification of cessation of securities - CYP
03/04/23		21.68KB	Share
CYP Cynata Adds New Sites for DFU Clinical Trial
16/03/23	PRICE SENSITIVE	260.1KB	Share
CYP Appendix 4D & Half-Year Financial Statements
28/02/23	PRICE SENSITIVE	815.32KB	Share
CYP Notification of cessation of securities - CYP
06/02/23		21.68KB	Share
CYP Quarterly Activity Report & Appendix 4C
31/01/23	PRICE SENSITIVE	507.29KB	Share
CYP Cynata Receives IRB Approval for aGvHD Clinical Trial
30/01/23	PRICE SENSITIVE	252.05KB	Share
CYP Notice of Acceptance for Cynata Australian Patent
09/01/23	PRICE SENSITIVE	249.94KB	Share
CYP Notification of cessation of securities - CYP
05/01/23		21.68KB	Share
CYP Cynata Receives $1.65m R&D Tax Incentive Refund
05/12/22	PRICE SENSITIVE	219.83KB	Share
CYP Appendix 3Y - Janine Rolfe
23/11/22		175.39KB	Share
CYP Notification regarding unquoted securities - CYP
23/11/22		27.78KB	Share
CYP Results of AGM
22/11/22		248.11KB	Share
CYP AGM Presentations
22/11/22		1.11MB	Share
CYP Conference Data Demonstrating Consistency of Cynata MSCs
16/11/22		274.81KB	Share
CYP Notice of Allowance for Cynata US Patent
11/11/22	PRICE SENSITIVE	249.75KB	Share
CYP Notification of cessation of securities - CYP
07/11/22		21.66KB	Share
CYP New Kidney Transplantation Clinical Trial for Cynata & LUMC
02/11/22	PRICE SENSITIVE	285.68KB	Share
CYP Quarterly Activity Report & Appendix 4C
31/10/22	PRICE SENSITIVE	509.47KB	Share
CYP Annual Report to Shareholders
21/10/22		6.5MB	Share
CYP Letter to Shareholders, Notice of AGM & Proxy Form
21/10/22		1.01MB	Share
CYP Notice of Allowance for Australia & Canada Cymerus Patents
17/10/22	PRICE SENSITIVE	249.47KB	Share
CYP Successful Completion of Planned DSMB Review of DFU Trial
12/10/22	PRICE SENSITIVE	257.57KB	Share
CYP Date of AGM and Closing Date for Director Nominations
27/09/22		216.12KB	Share
CYP Grant Award to Fund Study of Cynata MSCs in Heart Disease
26/09/22	PRICE SENSITIVE	281.79KB	Share
CYP Appendix 3X - Janine Rolfe
01/09/22		145.41KB	Share
CYP Appointment of Ms Janine Rolfe to the Cynata Board
30/08/22		249.69KB	Share
CYP Preclinical study in coronary artery disease published
29/08/22		256.27KB	Share
CYP Appendix 4G
24/08/22		286.93KB	Share
CYP Corporate Governance Statement
24/08/22		353.57KB	Share
CYP Appendix 4E & Annual Report
24/08/22	PRICE SENSITIVE	6.67MB	Share
CYP Pipeline Update Following Strategic Portfolio Review
12/08/22	PRICE SENSITIVE	309.54KB	Share

REFRESH

1 2 3 4 5 6

(20min delay)
Last 21.0¢		Change 0.000(0.00%)		Mkt cap ! $37.72M

Open	High	Low	Value	Volume
20.0¢	21.0¢	20.0¢	$4.156K	20.74K

Buyers (Bids)

No.	Vol.	Price($)
1	20000	20.0¢

Sellers (Offers)

Price($)	Vol.	No.
21.0¢	54635	3

View Market Depth

No.	Vol.	Price($)
1	20000	0.200
1	8187	0.195
2	31370	0.190
3	112017	0.185
1	10527	0.180

Price($)	Vol.	No.
0.210	54635	3
0.215	102183	2
0.220	149010	5
0.225	20000	1
0.230	130470	1

Last trade - 15.43pm 26/04/2024 (20 minute delay)

CYP (ASX) Chart

CYNATA THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories